Atypical antipsychotic drugs and glucose dysregulation [3]

Canadian Journal of Psychiatry

Volumn 47, Issue 1, 2002, Pages 94-96

  Baptista, Trino ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

DIABETES MELLITUS; DISEASE PREDISPOSITION; FAMILY HISTORY; GLUCOSE METABOLISM; HUMAN; LETTER; METABOLIC REGULATION; OBESITY; RISK FACTOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS; HUMANS; MENTAL DISORDERS;

EID: 0036215362     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (16)

1. Phenothiazines and diabetes in hospitalized women
2. New onset diabetes and atypical antipsychotics
3. Atypical antipsychotics and hyperglycaemia
4. Antipsychotic metabolic effects: Weight gain, diabetes mellitus and lipid anbormalities
5. New-onset diabetes mellitus associated with quetiapine
6. Olanzapine-related hyperglycemia in a nondiabetic woman
7. Pathogenesis ofT2D. A balanced overview
8. Prevalence and correlates of diabetes in national schizophrenia samples
9. Elevated frequency of diabetes mellitus in hospitalized manicdepressive patients
10. Endocrine and metabolic profile in the obesity associated to typical antipsychotic drug-administration
11. Body weight gain induced by antipsychotic drugs: Mechanisms and management
12. Binding ofantipsychotic drugs to human brain receptors: Focus on newer generation compounds
13. Risperidone-associated new-onset diabetes
14. Antipsychotic-induced weight gain: A comprehensive research synthesis
15. Effect of clozapine-quetiapine combination therapy on weight and glycemic control
16. Screening for type 2 diabetes